<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04916860</url>
  </required_header>
  <id_info>
    <org_study_id>SenL-T7 for CD7+leukemia/T-LBL</org_study_id>
    <nct_id>NCT04916860</nct_id>
  </id_info>
  <brief_title>Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma</brief_title>
  <official_title>Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Senlang Biotechnology Inc., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebei Senlang Biotechnology Inc., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open, single-arm, clinical study to evaluate efficacy and safety of anti CD7 CAR-T&#xD;
      cell in the treatment of relapsed and refractory CD7+ T-cell lymphoblastic leukemia or T-cell&#xD;
      lymphoblastic lymphoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open, prospective, dose-increasing clinical study with patients with&#xD;
      relapsed or refractory CD7+ T-cell lymphoblastic leukemia or T-cell lymphoblastic lymphoma as&#xD;
      subjects. In order to evaluate the safety and efficacy of SENL-T7 in patients with CD7+&#xD;
      T-cell lymphoblastic leukemia or T-cell lymphoblastic lymphoma, the PK/PD indicators of&#xD;
      SENL-T7 are also collected. In this study, no dose grouping is set, and 0.5-2E6 /kg× actual&#xD;
      body weight dose is selected for reinfusion according to patients' disease diagnosis and&#xD;
      tumor load.&#xD;
&#xD;
      The Main research objectives:&#xD;
&#xD;
      To evaluate the safety and efficacy of SENL-T7 in patients with relapsed or refractory CD7+&#xD;
      T-cell lymphoblastic leukemia or T-cell lymphoblastic lymphoma.&#xD;
&#xD;
      The Secondary research objectives:&#xD;
&#xD;
      To investigate the cellular dynamics of SENL-T7 CAR T cells in patients with relapsed or&#xD;
      refractory CD7+ T-cell lymphoblastic leukemia or T-cell lymphoblastic lymphoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 27, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Incidence and severity of adverse events</measure>
    <time_frame>First 1 month post CAR-T cells infusion</time_frame>
    <description>To evaluate the possible adverse events occurred within first one month after CD7 CAR-T infusion, including the incidence and severity of symptoms such as cytokine release syndrome and neurotoxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Remission Rate</measure>
    <time_frame>3 months post CAR-T cells infusion</time_frame>
    <description>To obsere the efficacy of CAR-T cells after infusion, complete remission (CR), complete remission with incomplete recovery of blood cells (CRi), minimal tumor residual positive(MRD+) or negative (MRD-) CR/CRi, disease recurrence or progression (PD) will be used for evaluation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>duration of response (DOR)</measure>
    <time_frame>24 months post CAR-T cells infusion</time_frame>
    <description>duration of response (DOR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAR-T proliferation</measure>
    <time_frame>3 months post CAR-T cells infusion</time_frame>
    <description>the copy number of CD7 CAR- T cells in the genomes of PBMC by qPCR method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>24 months post CAR-T cells infusion</time_frame>
    <description>progression-free survival (PFS) time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine release</measure>
    <time_frame>First 1 month post CAR-T cells infusion</time_frame>
    <description>Cytokine( IL-6,IL-10,IFN-γ,TNF-α ) concentration (pg/mL) by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAR-T proliferation</measure>
    <time_frame>3 months post CAR-T cells infusion</time_frame>
    <description>percentage of CD7 CAR- T cells measured by flow cytometry method</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>SenL-T7 CAR T Cells for CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma</condition>
  <arm_group>
    <arm_group_label>CD7 CAR-T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Senl-T7</intervention_name>
    <description>Patients will be treated with CD7 CAR-T cells</description>
    <arm_group_label>CD7 CAR-T</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of relapsed/refractory T-cell lymphoblastic leukemia or T-cell lymphoblastic&#xD;
             lymphoma: Induction therapy failed to achieve a complete remission of minor residual&#xD;
             negative; Recurrence: after complete remission, any tumor load in the peripheral blood&#xD;
             or bone marrow was 5%, or slightly residual positive, or new extramedullary lesions&#xD;
             occurred；&#xD;
&#xD;
          2. CD7 expression in tumor cells was detected by flow cytometry；&#xD;
&#xD;
          3. Life expectancy greater than 12 weeks；&#xD;
&#xD;
          4. KPS or Lansky score≥60;&#xD;
&#xD;
          5. HGB≥70g/L (can be transfused);&#xD;
&#xD;
          6. 2-70 years old;&#xD;
&#xD;
          7. oxygen saturation of blood#90%#;&#xD;
&#xD;
          8. Total bilirubin (TBil)≤3 × upper limit normal, aspartate aminotransferase (AST) and&#xD;
             alanine aminotransferase (ALT) ≤ 5×upper limit of normal;&#xD;
&#xD;
          9. Informed consent explained to, understood by and signed by patient/ guardian.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any of the following cardiac criteria: Atrial fibrillation/flutter; Myocardial&#xD;
             infarction within the last 12 months; Prolonged QT syndrome or secondary prolonged QT,&#xD;
             per investigator discretion. Cardiac echocardiography with LVSF (left ventricular&#xD;
             shortening fraction)&lt;30% or LVEF(left ventricular ejection fraction)&lt;50%; or&#xD;
             clinically significant pericardial effusion. Cardiac dysfunction NYHA(New York Heart&#xD;
             Association) III or IV (Confirmation of absence of these conditions on echocardiogram&#xD;
             within 12 months of treatment);&#xD;
&#xD;
          2. Has an active GvHD;&#xD;
&#xD;
          3. Has a history of severe pulmonary function damaging;&#xD;
&#xD;
          4. With other tumors which is/are in advanced malignant and has/have systemic metastasis;&#xD;
&#xD;
          5. Severe or persistent infection that cannot be effectively controlled;&#xD;
&#xD;
          6. Merging severe autoimmune diseases or immunodeficiency disease;&#xD;
&#xD;
          7. Patients with active hepatitis B or hepatitis C([HBVDNA+]or [HCVRNA&#xD;
&#xD;
             +]);&#xD;
&#xD;
          8. Patients with HIV infection or syphilis infection;&#xD;
&#xD;
          9. Has a history of serious allergies on Biological products (including antibiotics);&#xD;
&#xD;
         10. Clinically significant viral infection or uncontrolled viral reactivation of&#xD;
             EBV(Epstein-Barr virus), CMV(cytomegalovirus), ADV(adenovirus), BKvirus, or HHV(human&#xD;
             herpesvirus)-6.&#xD;
&#xD;
         11. Presence of symptomatic disorders of the central nervous system, which include but not&#xD;
             limited to uncontrolled epilepsy, cerebrovascular ischemia/hemorrhage, dementia, and&#xD;
             cerebellar disease, etc.;&#xD;
&#xD;
         12. Have received transplant treatment for less than 6 months in prior to enrollment;&#xD;
&#xD;
         13. Being pregnant and lactating or having pregnancy within 12 months;&#xD;
&#xD;
         14. Any situations that the researchers believe will increase the risks for the subject or&#xD;
             affect the results of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Peihua Lu, PhD</last_name>
    <phone>008618611636172</phone>
    <email>peihua_lu@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jianqiang Li, PhD</last_name>
    <phone>008615511369555</phone>
    <email>limmune@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hebei yanda Ludaopei Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peihua Lu, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 1, 2021</study_first_submitted>
  <study_first_submitted_qc>June 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2021</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

